Remarkable expansions of TRBV20-1 (Fig. 6f) and TRBJ2-5 (Fig. 6g) co-occurred in both MPR patients (P16 and P18) but not in other patients, suggesting that TRBV20-1 and TRBJ2-5 might contribute to anti-tumor immunity. The gene discussed is TRBV20-1; the disease is neoplasm.